title: Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
authors.affiliation: Multidisciplinary Breast Center; Department of Obstetrics and Gynecology, UZ-Leuven, Catholic University Leuven, Leuven, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Neven
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
authors.forename: F
authors.initials: F
authors.lastname: Amant
authors.forename: H
authors.initials: H
authors.lastname: Wildiers
authors.forename: P
authors.initials: P
authors.lastname: Berteloot
authors.forename: K
authors.initials: K
authors.lastname: Leunen
authors.forename: A
authors.initials: A
authors.lastname: Smeets
authors.forename: C
authors.initials: C
authors.lastname: Weltens
authors.forename: W
authors.initials: W
authors.lastname: van den Bogaert
authors.forename: E
authors.initials: E
authors.lastname: van Limbergen
authors.forename: M R
authors.initials: MR
authors.lastname: Christiaens
authors.forename: I
authors.initials: I
authors.lastname: Vergote
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism*; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D013629:Tamoxifen